ABRDN LIFE SCIENCES INVESTOR (HQL)

US87911K1007

13.89  +0.04 (+0.29%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ABRDN LIFE SCIENCES INVESTOR

NYSE:HQL (5/13/2024, 6:30:52 PM)

13.89

+0.04 (+0.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap379.89M
Shares
PE15.97
Fwd PEN/A
Dividend Yield9.6%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

ETF Stock Screener

Find more ETFs on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

HQL Daily chart

Company Profile

Abrdn Life Sciences Investors is a US-based company operating in industry. The company is headquartered in Boston, Massachusetts. abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.

Company Info

ABRDN LIFE SCIENCES INVESTOR

100 Federal Street, 19th Floor

Boston MASSACHUSETTS 02109

P: 16177728515

CEO: Daniel R. Omstead

Employees: 0

Website: https://www.teklacap.com/funds/hql/fund/fund-information/

HQL News

News Imagea month ago - Market News VideoHQL Crosses Below Key Moving Average Level
News Image3 months ago - Seeking Alphaabrdn Life Sciences Investors raises dividend by 30% to $0.39 (NYSE:HQL)

abrdn Life Sciences Investors (NYSE:HQL) declares $0.39/share quarterly dividend, 30% increase from prior dividend of $0.30.Forward yield 11.26%Payable...

News Image7 months ago - Tekla Capital Management LLCTekla Funds Approve New Investment Advisory Agreements With abrdn Inc.
News Image7 months ago - Tekla Capital Management LLCTekla Capital Management LLC Announces Closing of Transaction With abrdn
News Image7 months ago - Tekla Capital Management LLCTekla Funds Implore Shareholders of THQ and THW to Vote Immediately to Realize Potential Cost Savings for the Funds
News Image7 months ago - Tekla Capital Management LLCTekla Funds Urge Shareholders to Vote Immediately to Guarantee Reduced Fund Expenses

HQL Twits

Here you can normally see the latest stock twits on HQL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example